Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY Registry (2016) Schmieder R, Bramlage P Journal article, Letter Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry (2016) Kistner I, Zeymer U, Dechend R, Hagedorn I, Riemer T, Bramlage P, Pittrow D, et al. Journal article Seasonal Variation in Blood Pressure in 162,135 Patients With Type 1 or Type 2 Diabetes Mellitus (2016) Hermann JM, Rosenbauer J, Dost A, Steigleder-Schweiger C, Kiess W, Schöfl C, Holl RW Journal article Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry (2015) Schmieder R, Potthoff SA, Bramlage P, Baumgart P, Mahfoud F, Buhck H, Ouarrak T, et al. Journal article Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome (2015) Raff U, Walker SE, Ott C, Schneider MP, Schmieder R Journal article Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2) (2014) Bramlage P, Zemmrich C, Gansz A, Sturm CD, Fimmers R, Nadal J, Schmieder R, et al. Journal article The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium (2014) Campbell N, Lackland D, Chockalingam A, Liu Lisheng , Schiffrin EL, Harrap S, Touyz RM, et al. Journal article